Larimar Therapeutics, Inc. (LRMR)
LRMR moved a median of -0.17% 30 minutes after news, and 0.00% by the close. How LRMR actually reacts to news — the realized, point-in-time move the market made, measured across 258 labeled events over the last three years with zero look-ahead.
LRMR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.13% | 45% | 258 |
| 30-min | -0.17% | 48% | 258 |
| 60-min | 0.00% | 48% | 258 |
| to close | 0.00% | 49% | 258 |
| Middle 50% of LRMR reactions | -1.52% to +2.01% |
|---|---|
| Median reaction (30-min) | -0.17% |
| Measured reactions | 258 |
Half of all Larimar Therapeutics, Inc. news events land between -1.52% and +2.01% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LRMR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 26 | +0.70% | 54% | -0.84% |
| Rating reiterations | 47 | +0.10% | 51% | -0.73% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how LRMR ranks against every other measured name →
That’s how LRMR usually reacts — get an email when it moves on news →Email me when LRMR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LRMR's baseline. Nothing else.
Recent LRMR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Larimar Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.16% | +2.08% | |
| Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer | Press release | GlobeNewswire | -0.16% | +2.08% | |
| Form 10-Q Larimar Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.00% | +3.27% | |
| Form 8-K Larimar Therapeutics, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +3.27% | |
| Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update | Press release | GlobeNewswire | -1.00% | +3.27% | |
| Form 8-K Larimar Therapeutics, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +2.02% | +7.74% | |
| Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia | Press release | GlobeNewswire | +2.02% | +7.74% | |
| Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia | Press release | GlobeNewswire | +2.02% | +7.74% | |
| Form 8-K Larimar Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | +5.37% | |
| Form 10-Q Larimar Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.38% | -7.01% | |
| Form 8-K Larimar Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.87% | -6.04% | |
| Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update | Press release | GlobeNewswire | -3.87% | -6.04% | |
| Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia | Press release | GlobeNewswire | -0.25% | -2.48% | |
| Form ARS Larimar Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.49% | -5.19% | |
| Form DEF 14A Larimar Therapeutics, For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -2.49% | -5.19% | |
| Form PRE 14A Larimar Therapeutics, For: May 19 | SEC filing · Form PRE | SEC EDGAR | -2.47% | +0.21% | |
| Form 10-K Larimar Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.22% | -1.00% | |
| Form 8-K Larimar Therapeutics, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | +4.68% | |
| Form S-8 Larimar Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -2.43% | -0.66% | |
| Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.41% | +4.68% | |
| Larimar Therapeutics to Participate in Upcoming Investor Conferences in March | Press release | GlobeNewswire | +2.05% | -2.61% | |
| Form 8-K Larimar Therapeutics, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -1.26% | -4.15% | |
| Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering | Press release | GlobeNewswire | +0.86% | +2.60% | |
| Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering | Press release | GlobeNewswire | +0.86% | +2.60% | |
| Form 8-K Larimar Therapeutics, For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +8.99% | +3.36% | |
| Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 | Press release | GlobeNewswire | +8.99% | +3.36% | |
| Form 8-K Larimar Therapeutics, For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +3.60% | |
| Form 8-K Larimar Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +3.10% | |
| Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.29% | -2.00% | |
| Form 8-K Larimar Therapeutics, For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +1.20% | -7.49% | |
| Form 8-K Larimar Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -0.56% | |
| Form 10-Q Larimar Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +8.78% | |
| Form 8-K Larimar Therapeutics, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -9.80% | |
| Larimar Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.54% | -9.80% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Larimar Therapeutics, Inc. (LRMR) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.09% | -5.61% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Larimar Therapeutics, Inc. (LRMR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.12% | -4.04% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutics, Inc. (LRMR) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.12% | +0.58% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutics, Inc. (LRMR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.17% | +1.88% | |
| Larimar Therapeutics, Inc. (LRMR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.25% | -1.13% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Larimar Therapeutics, Inc. (LRMR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.12% | -1.49% | |
| Larimar Therapeutics, Inc. (LRMR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -1.29% | +2.35% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Larimar Therapeutics, Inc. (LRMR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.26% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutics, Inc. (LRMR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.36% | +1.21% | |
| Form 8-K Larimar Therapeutics, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -0.24% | -6.25% | |
| Form 8-K Larimar Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +8.96% | -5.06% | |
| Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia | Press release | GlobeNewswire | +8.96% | -5.06% | |
| Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia | Press release | GlobeNewswire | +8.96% | -5.06% | |
| Form 10-Q Larimar Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.31% | +1.31% | |
| Form 8-K Larimar Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +1.62% | +14.82% | |
| Larimar Therapeutics Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.62% | +14.82% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LRMR section they belong to.
Where else LRMR is measured.
LRMR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Larimar Therapeutics, Inc.'s median reaction calculated?
Every labeled LRMR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 258 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of LRMR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LRMR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.